Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant CD22 (Epratuzumab Biosimilar) anticorps

Reactivité: Cynomolgus, Humain, Macaque rhésus BP, FACS, IP Hôte: Human Monoclonal hL22 unconjugated Recombinant Antibody
N° du produit ABIN5668216
  • Antigène Tous les produits CD22 (Epratuzumab Biosimilar)
    CD22 (Epratuzumab Biosimilar)
    Type d'anticorp
    Recombinant Antibody
    Reactivité
    Cynomolgus, Humain, Macaque rhésus
    Hôte
    • 1
    Human
    Clonalité
    • 1
    Monoclonal
    Conjugué
    • 1
    Cet anticorp CD22 (Epratuzumab Biosimilar) est non-conjugé
    Application
    Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)
    Specificité
    This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
    Attributs du produit

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Purification
    Purified antibody.
    Pureté
    > 98 % as determined by SDS-PAGE
    niveau d'endotoxine
    Endotoxin is < 1.0 EU/mg as determined by the LAL method
    Immunogène
    This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
    Clone
    HL22
    Isotype
    IgG1 kappa
  • Indications d'application
    Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).
    Restrictions
    For Research Use only
  • Buffer
    PBS with 0.02 % Proclin 300.
    Agent conservateur
    ProClin
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Antigène
    CD22 (Epratuzumab Biosimilar)
    Abstract
    CD22 (Epratuzumab Biosimilar) Produits
    Synonymes
    anticorps SIGLEC-2, anticorps SIGLEC2, anticorps CD22 molecule, anticorps CD22
    Classe de substances
    Biosimilar
    Sujet
    Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14
    UniProt
    P20273
Vous êtes ici:
Support technique